Ligand Pharmaceuticals
LGND Mid CapHealthcare · Biotechnology
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Ligand Pharmaceuticals en bref
Ligand Pharmaceuticals (LGND) is currently trading at 249,30 € with a market capitalization of 5,0 Md €. The trailing P/E ratio stands at 37.44x, with a forward P/E of 24.31x. The 52-week range spans from 114,16 € to 283,19 €; the current price is 12% below the yearly high. Year-over-year revenue growth stands at +14.1%. The net profit margin stands at 55.95%.
💰 Dividende
Ligand Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
10 analystes évaluent Ligand Pharmaceuticals (LGND) au consensus : Achat Fort. L'objectif de cours moyen est de 280,30 €, soit un potentiel de +12.44% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 214,15 € à 336,40 €.
Ligand Pharmaceuticals : la thèse d'investissement en détail
Ligand Pharmaceuticals (LGND) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Revenue is growing at a healthy 14.1% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 83.16%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 55.95%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.
Le scénario baissier
Short interest sits at 11.47% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valorisation en contexte
The EV/EBITDA multiple of 40.43x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
À surveiller
- The forward P/E of 24.31x is meaningfully below the trailing 37.44x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Rentable avec une marge nette de 55.95%
- Rentabilité élevée des capitaux propres (17.13% ROE)
- Marge brute élevée de 83.16% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Strong Buy
- Bilan solide avec faible endettement (D/E 45.32)
- Free cash flow positif
- –Actuellement jugée surévaluée
- –Positions vendeuses élevées (11.47%)
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (11.47%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Ligand Pharmaceuticals?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news